Document Type
Article
Date of Original Version
2018
Department
Pharmacy Practice
Abstract
On December 8, 2016, the New England Journal of Medicine published a sounding board on Real World Evidence (RWE)1 by the US Food and Drug Administration (FDA) leadership. While the value of RWE based on nonrandomized observational studies was appreciated, such as for hypothesis generating, safety, and measuring quality in healthcare delivery, the authors expressed concerns on the quality of data sources and the ability of methodologies to control for confounding. In response, we offer a few considerations regarding these concerns.
Citation/Publisher Attribution
Yuan, H., Ali, M.S., Brouwer, E.S., Girman, C.J., Guo, J.J., Lund, J.L., & Bennett, D.(2018), Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG). Clin. Pharmacol. Ther., 104(2), 239-241. https://doi.org/10.1002/cpt.1086 Available at: https://doi.org/10.1002/cpt.1086
Author Manuscript
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable
towards Open Access Policy Articles, as set forth in our Terms of Use.